Arexvy, an RSV vaccine, can reduce the risk of developing RSV-related lower respiratory tract disease by 94.1%, according to the Food and Drug Administration (FDA)
Give It Time Semaglutide is typically started at a lower dose and gradually increased over several weeks or months
Current Medical Research and Opinion , 27 (1), 8798
Prices vary by brand, dosage, and insurance coverage
In a landmark study called the STEP program, which included over 4500 adults with overweight or obesity, glp-1 was found to lead to significant weight loss compared to a placebo
In December the TGA added this indication under the heading Reduction in risk of major adverse cardiovascular events: Wegovy is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a Body Mass Index (BMI) 27kg/m2, and without established Type 1 or Type 2 diabetes. The decision to approve the Wegovy-branded semaglutide product was based on the SELECT study published in late 2023 a large international trial, backed by maker Novo Nordisk, involving around 18,000 non-diabetic patients with a BMI of at least 27